Table 2.
Univariate Cox Regression of Adverse Clinical Outcomes at Follow-Up
| Unadjusted HR (95% CI) | P Value | |
|---|---|---|
| Age, y | 1.03 (1.02–1.04) | <0.001 |
| Body mass index, g/m2 | 0.98 (0.96–0.99) | 0.009 |
| Systolic blood pressure, mm Hg | 0.99 (0.99–1.01) | 0.158 |
| Diastolic blood pressure, mm Hg | 0.98 (0.97–0.99) | <0.001 |
| Male | 1.22 (1.04–1.42) | 0.016 |
| Hypertension | 1.05 (0.88–1.26) | 0.560 |
| Diabetes mellitus | 1.08 (0.92–1.27) | 0.925 |
| Hyperlipidemia | 1.02 (0.87–1.19) | 0.847 |
| Atrial fibrillation | 1.28 (1.03–1.59) | 0.027 |
| Ischemic heart disease | 1.29 (1.10–1.52) | 0.002 |
| Left ventricular internal diameter in diastole, mm | 1.01 (0.99–1.01) | 0.897 |
| End-diastolic volume index, mL/m2 | 1.01 (0.99–1.01) | 0.236 |
| Stroke volume index, mL/m2 | 0.99 (0.99–1.01) | 0.865 |
| Left ventricular ejection fraction, % | 0.98 (0.97–0.99) | 0.002 |
| Left ventricular mass index, g/m2 | 1.01 (1.00–1.01) | <0.001 |
| Left atrial diameter, mm | 1.03 (1.02–1.04) | <0.001 |
| Peak transaortic velocity, cm/s | 1.01 (1.00–1.01) | <0.001 |
| Transaortic mean pressure gradient, mm Hg | 1.01 (1.01–1.02) | <0.001 |
| Aortic valve area, cm2 | 0.48 (0.37–0.63) | <0.001 |